ENX-104 boosts dopamine and serotonin in rat brain

Dec. 19, 2023

Researchers from Engrail Therapeutics Inc. presented preclinical data for the novel D2/3 receptor antagonist ENX-104, being developed for the treatment of depression.

BioWorld Science Conferences Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for May 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 14, 2025.

FDA shift from animal testing fuels organoid, organ-on-chip demand

BioWorld Science

The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing technologies like organoids and...

Septerna joins a $2.2B obesity deal with Novo

BioWorld

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral...

Sonomind ultrasounds brain stimulation system

Sonomind’s TUS device reduces depressive symptoms

BioWorld MedTech

A low-intensity transcranial ultrasound stimulation device, developed by Sonomind SAS, was proven to be safe and effective in treating patients suffering from...